February 17, 2022
Following the efforts of Adicet Bio, formerly resTORbio, to create therapies based on the mTOR pathway, Cambrian Biopharma is working with Novartis to use this pathway in order to increase healthspan and lifespan. The full press release is included here. NEW YORK, Feb. 16, 2022 /PRNewswire/ -- Cambrian Biopharma, a multi-asset longevity biotech, today announced a licensing...